| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 76.84 CAD | 0.00 (0.00%) | 43.99 - 80.64 | 0.0 |
Market data as of 4:00PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 76.84 |
| Day's Range | -- - -- |
| Market Cap | 23.3B |
| Avg Volume (10 Day) | 622.5K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | |
| Dividend Yield | No Dividend |
Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
PR Newswire - Tuesday 05/21/2013 5:00 PM ET
Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
PR Newswire - Monday 05/20/2013 5:00 PM ET
Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors
PR Newswire - Wednesday 05/15/2013 8:15 PM ET
Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
PR Newswire - Monday 05/13/2013 5:00 PM ET
Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
PR Newswire - Friday 05/10/2013 5:00 PM ET
Valeant Pharmaceuticals Provides Efinconazole Update
PR Newswire - Thursday 05/02/2013 8:14 PM ET
Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
PR Newswire - Thursday 05/02/2013 6:00 AM ET
Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
PR Newswire - Wednesday 05/01/2013 8:00 AM ET
| TSE:VRX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|
Data is delayed by at least 15 min.